AIMS: Searching for EGFR and KRAS mutations within non-small cell lung carcinoma (NSCLC) samples remains time-consuming and can delay treatment choices in patients with acute deterioration. We evaluated the performances of the fully automated Idylla platform to quickly detect these mutations in NSCLC samples. METHODS: We used the Idylla EGFR Mutation Assay and the Idylla KRAS Mutation Test to analyse 18 formalin-fixed paraffin-embedded NSCLC tumour samples with known EGFR and KRAS mutation status according to next-generation sequencing (NGS) and droplet digital PCR (ddPCR) for EGFRT790M mutations. RESULTS: Idylla assays identified KRAS and EGFR activating mutations in 4 and 10 NSCLC samples, respectively. EGFRT790M resistance mutations were identified in only 1 sample using Idylla but in 4 and 14 samples using NGS and ddPCR, respectively. No false-positive result was noted with Idylla assays. Mutation written report was obtained after 130 min (KRAS assays) to 140 min (EGFR assays). CONCLUSIONS: The Idylla platform is an interesting ancillary first-line fast and fully automated tool to detect EGFR and KRAS mutations in NSCLC samples allowing rapid treatment choices in patients with acute deterioration. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
AIMS: Searching for EGFR and KRAS mutations within non-small cell lung carcinoma (NSCLC) samples remains time-consuming and can delay treatment choices in patients with acute deterioration. We evaluated the performances of the fully automated Idylla platform to quickly detect these mutations in NSCLC samples. METHODS: We used the Idylla EGFR Mutation Assay and the Idylla KRAS Mutation Test to analyse 18 formalin-fixed paraffin-embedded NSCLC tumour samples with known EGFR and KRAS mutation status according to next-generation sequencing (NGS) and droplet digital PCR (ddPCR) for EGFRT790M mutations. RESULTS: Idylla assays identified KRAS and EGFR activating mutations in 4 and 10 NSCLC samples, respectively. EGFRT790M resistance mutations were identified in only 1 sample using Idylla but in 4 and 14 samples using NGS and ddPCR, respectively. No false-positive result was noted with Idylla assays. Mutation written report was obtained after 130 min (KRAS assays) to 140 min (EGFR assays). CONCLUSIONS: The Idylla platform is an interesting ancillary first-line fast and fully automated tool to detect EGFR and KRAS mutations in NSCLC samples allowing rapid treatment choices in patients with acute deterioration. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Maria-Rosa Ghigna; Adrian Crutu; Valentina Florea; Séverine Feuillet-Soummer; Pierre Baldeyrou; Julien Adam; Ludovic Lacroix; Benjamin Besse; Olaf Mercier; Elie Fadel; Peter Dorfmuller; Rida El Ayoubi; Vincent Thomas de Montpréville Journal: J Thorac Dis Date: 2018-07 Impact factor: 2.895
Authors: Amir Momeni-Boroujeni; Paulo Salazar; Tao Zheng; Nana Mensah; Ivelise Rijo; Snjezana Dogan; JinYuan Yao; Christine Moung; Chad Vanderbilt; Jamal Benhamida; Jason Chang; William Travis; Natasha Rekhtman; Marc Ladanyi; Khedoudja Nafa; Maria E Arcila Journal: J Mol Diagn Date: 2020-12-18 Impact factor: 5.568
Authors: Maria E Arcila; Soo-Ryum Yang; Amir Momeni; Douglas A Mata; Paulo Salazar; Roger Chan; Daniela Elezovic; Ryma Benayed; Ahmet Zehir; Darren J Buonocore; Natasha Rekhtman; Oscar Lin; Marc Ladanyi; Khedoudja Nafa Journal: JTO Clin Res Rep Date: 2020-07-18
Authors: M Rabie Al-Turkmani; Michael A Suriawinata; Sophie J Deharvengt; Donald C Green; Candice C Black; Keisuke Shirai; Konstantin H Dragnev; Gregory J Tsongalis Journal: Pract Lab Med Date: 2020-03-02